Articles

Adding the antiplatelet drug ticagrelor (Brilinta) to aspirin as long-term therapy after a heart attack significantly reduced the rate of subsequent death from cardiovascular causes, heart attack...

Bendavia, heart attack, scarring, angioplasty, ACC, study

Patients who received the new drug Bendavia before undergoing angioplasty or stent implantation after a heart attack showed no significant reduction in scarring compared to patients given a...

BEST Trial

Despite the advent of a new generation of stents, patients with multiple narrowed arteries in the heart who received coronary artery bypass grafting fared better than those whose arteries were...

A novel therapy that would allow doctors to turn the body’s blood clotting ability off and on in a more controlled way was about as effective as established anticoagulants in patients undergoing...

Bonn Call for Action, FDA, radiation exposure, medical imaging, update

The U.S. Food and Drug Administration (FDA) announced its latest efforts in supporting the Bonn Call for Action, an international list of priorities for radiation protection in medicine for the...

Impella, FDA, high risk PCI, abiomed

The U.S. Food and Drug Administration (FDA) has granted pre-market approval (PMA) clearance for Abiomed’s Impella 2.5 heart pump during elective and urgent high-risk percutaneous coronary...

Patients over age 80 with acute coronary syndromes would likely benefit from more invasive tests and therapies that may otherwise be denied them due to their age, according to research presented...

atients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two coprimary endpoints — a composite...

dual antiplatelet therapy, DAPT, mortality, DES implantation, CRF, length

Data from a meta-analysis published recently in The Lancet found that extended-duration dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation was associated with...

TriGuard, Keystone, embolic protection, TAVR

March 19, 2015 — An investigational device that deflects debris away from the brain during transcatheter aortic valve replacement (TAVR) seems to improve in-hospital safety outcomes and cognitive...